Bone Marrow-Derived Endothelial Progenitor Cells Reduce Recurrent Miscarriage in Gestation
Cell Transplantation
|August 12, 2016
Summary
Transfusing endothelial progenitor cells (EPCs) into mice significantly reduced miscarriage rates by promoting placental neovascularization. This therapy may offer a novel approach for preventing recurrent pregnancy loss.
Area of Science:
- Reproductive biology
- Vascular biology
- Cell therapy
Background:
- Reduced placental neovascularization and elevated soluble Flt1 are linked to recurrent miscarriages.
- Endothelial progenitor cells (EPCs) are crucial for angiogenesis and tissue formation.
Purpose of the Study:
- To investigate if VEGF-expressing EPC transfusion can prevent miscarriage in a mouse model.
- To explore the role of the VEGF-eNOS signaling pathway in EPC-mediated neovascularization.
Main Methods:
- Systemic transfusion of VEGF-expressing EPCs in a mouse miscarriage model.
- Analysis of placental vascularization, EPC infiltration, and miscarriage rates.
- In vitro studies on EPC function under soluble Flt1 treatment.
Main Results:
- EPC transfusion significantly decreased miscarriage rates.
- Recruited EPCs normalized placental vascular patterns and vessel size.
- Soluble Flt1 was found to inhibit EPC function and eNOS expression in vitro.
Conclusions:
- Autologous EPC therapy shows promise for preventing miscarriage in high-risk pregnancies.
- Targeting the VEGF-eNOS pathway via EPCs may improve placental development.
